Single nucleotide polymorphisms in TP53 but not KRAS or MDM2 are predictive of clinical outcome in multiple myeloma treated with high-dose melphalan and autologous stem cell support.
Leuk Lymphoma
; 57(6): 1482-6, 2016.
Article
in En
| MEDLINE
| ID: mdl-26414189
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Tumor Suppressor Protein p53
/
Proto-Oncogene Proteins p21(ras)
/
Polymorphism, Single Nucleotide
/
Proto-Oncogene Proteins c-mdm2
/
Multiple Myeloma
Type of study:
Prognostic_studies
/
Risk_factors_studies
Limits:
Humans
Language:
En
Journal:
Leuk Lymphoma
Journal subject:
HEMATOLOGIA
/
NEOPLASIAS
Year:
2016
Type:
Article